SUSTAINED SURVIVAL ADVANTAGE AFTER A MEDIAN FOLLOW-UP OF 5 YEARS FOR IMMUNO-CHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA - UPDATE OF THE OSHO#39 TRIAL

被引：0
|
作者：
Herold, M. [1 ]
Maschmeyer, G. [2 ]
Lakner, V. [3 ]
Doelken, G. [4 ]
Ehninger, G. [5 ]
Haenel, M. [6 ]
Rohrberg, R. [3 ]
Hochhaus, A. [7 ]
Neubauer, A. [7 ]
Fischer, L. [8 ]
von Gruenhagen, U. [3 ]
Hahnfeld, S. [3 ]
Hoffmann, F. [3 ]
Wussling, M. [3 ]
Stein, W. [9 ]
Kettner, E. [10 ]
Haehling, D. [11 ]
机构：
[1] Helios Klinikum Erfurt, Ertfurt, Germany
[2] Klinikum Ernst Von Bergmann, Potsdam, Germany
[3] Onkolog Praxis, Rostock, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany
[5] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[6] Klinikum Chemitz, Chemnitz, Germany
[7] Univ Klinikum Jena, Jena, Germany
[8] Charite, Berlin, Germany
[9] Klinikum Frankfurt, Frankfurt, Germany
[10] Stadt Klinikum, Magdeburg, Germany
[11] HELIOS Klin, Schwerin, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0575
引用
收藏
页码：239 / 239
页数：1
相关论文
共 10 条
  • [1] IMPROVED SURVIVAL AFTER A MEDIAN FOLLOW-UP OF 6 YEARS FOR IMMUNOCHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA (FL) - UPDATE OF THE OSHO#39 TRIAL
    Herold, M.
    Maschmeyer, G.
    Lakner, V.
    Doelken, G.
    Ehninger, G.
    Haenel, M.
    Hochhaus, A.
    Rohrberg, R.
    Neubauer, A.
    Fischer, L.
    Al-Ali, H.
    Wussling, M.
    Haehling, D.
    Hahnfeld, S.
    Hoffmann, F. A.
    Kahl, C.
    ANNALS OF ONCOLOGY, 2011, 22 : 88 - 88
  • [2] Survival advantage for immunochemotherapy (R-MCP) over chemotherapy (MCP) alone in advanced follicular lymphoma after a median follow up of 5 years - updated results of the OSHO#39 study
    Herold, M.
    Maschmeyer, G.
    Lakner, V
    Doelken, G.
    Ehninger, G.
    Haenel, M.
    Rohrberg, R.
    ONKOLOGIE, 2010, 33 : 132 - 132
  • [3] Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone -: 50 months up date of the OSHO phase III study (OSHO#39)
    Herold, M.
    Haas, A.
    Doerken, B.
    Neser, S.
    Al Ali, K. H.
    Neubauer, A.
    Doelken, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 85
  • [4] Immunochemotherapy (R-MCP) is not superior to chemotherapy (MCP) alone in advanced mantle cell lymphoma - 42 months follow up results of the OSHO 39 study
    Herold, Michael
    Haas, Antje
    Stock, Stephanie
    Neser, Sabine
    Al Ali, Kathrin H.
    Neubauer, Andreas
    Doelken, Gottfried
    Naumann, Ralph
    Fietz, Thomas
    Freund, Mathias
    Rohrberg, Robert
    Hoeffken, Klaus
    Mohren, Martin
    Ittel, Thomas H.
    Kettner, Erika
    BLOOD, 2007, 110 (11) : 189B - 189B
  • [5] Immunochemotherapy (R-MCP) prolongs survival in advanced follicular lymphoma -: 50 months up-date of a phase III study of the east German study group hematology and oncology (OSHO#39)
    Herold, M.
    Haas, A.
    Doerken, B.
    Neser, S.
    Al Ali, K. H.
    Neubauer, A.
    Doelken, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 180 - 181
  • [6] Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year follow-up results of a phase III trial of the east German study group hematology and oncology (OSHO#39).
    Herold, Michael
    Haas, Antje
    Srock, Stephanie
    Neser, Sabine
    Al Ali, Kathrin H.
    Neubauer, Andreas
    Doelken, Gottfried
    Naumann, Ralph
    Fietz, Thomas
    Freund, Mathias
    Rohrberg, Robert
    Hoeffken, Klaus
    Franke, Astrid
    Ittel, Thomas H.
    Kettner, Erika
    BLOOD, 2006, 108 (11) : 147A - 147A
  • [7] Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Dreyling, MH
    Forstpointner, R
    Ludwig, WD
    Gramatzki, M
    Boeck, HP
    Haenel, M
    Wandt, H
    Parwaresch, R
    Unterhalt, M
    Hiddemann, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 567S - 567S
  • [8] Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
    Provencio, Mariano
    Franco, Fernando
    Gomez-Codina, Jose
    Quero Blanco, Cristina
    Llanos, Marta
    Garcia-Arroyo, Francisco
    de la Cruz, Luis
    Guma, Josep
    Ramon Delgado, Juan
    Alvarez, Ruth
    Ignacio Chacon, Jose
    Royuela, Ana
    Rueda, Antonio
    LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 856 - 859
  • [9] High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years
    Gyan, Emmanuel
    Foussard, Charles
    Bertrand, Philippe
    Michenet, Patrick
    Le Gouill, Steven
    Berthou, Christian
    Maisonneuve, Herve
    Delwail, Vincent
    Gressin, Remi
    Quittet, Philippe
    Vilque, Jean-Pierre
    Desablens, Bernard
    Jaubert, Jerome
    Ramee, Jean-Francois
    Arakelyan, Nina
    Thyss, Antoine
    Molucon-Chabrot, Cecile
    Delepine, Roselyne
    Milpied, Noel
    Colombat, Philippe
    Deconinck, Eric
    BLOOD, 2009, 113 (05) : 995 - 1001
  • [10] High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin's Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years
    Gastinne, Thomas
    Damaj, Gandhi
    Lamy, Thierry
    Ifrah, Norbert
    Deconinck, Eric
    Gressin, Remy
    Colombat, Philippe
    Delwail, Vincent
    Berthou, Christian
    Rossi, Jean Francois
    Harousseau, Jean Luc
    Milpied, Noel-Jean
    BLOOD, 2008, 112 (11) : 286 - 286
1